Search

everythinglearnresearchcommunity

for

Search:↓

IL-17 and certain immune cells are linked to more severe alopecia areata.

Autoimmune hepatitis in children often affects girls and can be treated successfully with medication.

Alopecia areata was successfully treated with contact immunotherapy, oral antihistamines, and topical corticosteroids.

New treatments like biologics and JAK inhibitors show promise for severe scalp inflammation when traditional methods fail.

Cardamonin reduces inflammation in gum tissue cells.

COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.

Chikungunya virus often causes skin issues and inflammation.

PD‐L1 and PD‐L2 may not effectively control immune activation in alopecia areata.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

Intralesional cidofovir might be a viable alternative treatment for certain conditions.

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

IL-13 protein is much higher in the skin of atopic dermatitis patients than in healthy skin.

Inflammation affects hair loss; anti-inflammatory treatments may help.

Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.

Unique microRNA patterns can help diagnose and treat severe alopecia areata.

Early biopsy and targeting inflammation can improve treatment for hair loss in androgenetic alopecia.

Stopping azathioprine improved hair loss and bone marrow issues.

Skin and mucous symptoms are key for diagnosing autoimmune connective tissue diseases.

Adults with certain skin conditions may have higher levels of inflammation in their body.

Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Targeting SIRT1 with antisense oligonucleotides could be a promising treatment for hair loss.

Loss of OGG1 increases skin inflammation and auto-antibodies in lupus.

Skin cells and immune cells change in a skin condition called hidradenitis suppurativa, and a certain treatment can improve these changes.

Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.

CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss.

FK506 may stimulate hair growth when applied to the skin.

Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.